

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, 1/21, 15/63, 15/11, C07H 21/04, 21/02, C07K 14/00, A61K 38/00	A1	(11) International Publication Number: WO 99/13066 (43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/US98/18724		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 8 September 1998 (08.09.98)		
(30) Priority Data: 08/929,007 8 September 1997 (08.09.97) US		
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).		
(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 111 Locust Street #41, Woburn, MA 01801 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US).		
(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).		

Published*With international search report.*

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

(57) Abstract

Novel polynucleotides and proteins encoded by or related to SEQ ID NO:1 and SEQ ID NO:2 are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5 This application is a continuation-in-part of application Ser. No. 60/093,045 (converted to a provisional application from non-provisional application Ser. No. 08/929,007), filed September 8, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

15 Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein
20 in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of
25 DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

30

35

40

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 69 to nucleotide 908;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 270 to nucleotide 908;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 69 to nucleotide 908; the nucleotide sequence of SEQ ID NO:1 from nucleotide 270 to nucleotide 908; the nucleotide sequence of the full-length protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535; or the

nucleotide sequence of a mature protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535. In yet other preferred embodiments,

5 the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 83. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most

10 preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
15 ID NO:1.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- 20 (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 83;
- (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
- (d) the amino acid sequence encoded by the cDNA insert of clone
25 bn97_1 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 83. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
 - 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 562 to nucleotide 777;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 236 to nucleotide 673;
 - 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bn268_11 deposited under accession number ATCC 98535;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
 - 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bn268_11 deposited under accession number ATCC 98535;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
 - 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
 - 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 562 to nucleotide 777; the nucleotide sequence of SEQ ID NO:3 from nucleotide 236 to nucleotide 673; the nucleotide sequence of the full-length protein coding sequence of clone bn268_11 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone bn268_11 deposited

under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
 - (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 37;
 - (c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 286 to nucleotide 1686;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 544 to nucleotide 1686;
- 10 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 365 to nucleotide 1160;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535;
- 15 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535;
- 20 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- 25 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- 30 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 286 to nucleotide 1686; the nucleotide sequence of SEQ ID NO:5 from nucleotide 544 to nucleotide 1686; the nucleotide sequence of SEQ ID NO:5 from

nucleotide 365 to nucleotide 1160; the nucleotide sequence of the full-length protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535. In other preferred embodiments, the 5 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 28 to amino acid 395. In further preferred embodiments, the present invention provides a polynucleotide 10 encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence 15 from amino acid 228 to amino acid 237 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 20 consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 28 to amino acid 395;
- (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising 25 eight consecutive amino acids of SEQ ID NO:6; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence 30 of SEQ ID NO:6 from amino acid 28 to amino acid 395. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6

having biological activity, the fragment comprising the amino acid sequence from amino acid 228 to amino acid 237 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 99 to nucleotide 1049;
- 10 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 222 to nucleotide 1049;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 632 to nucleotide 998;
- 15 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;
- 20 (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- 25 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 30 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 99 to nucleotide 1049; the nucleotide sequence of SEQ ID NO:7 from nucleotide 222 to nucleotide 1049; the nucleotide sequence of SEQ ID NO:7 from nucleotide 632 to nucleotide 998; the nucleotide sequence of the full-length protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8 from amino acid 187 to amino acid 300. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 153 to amino acid 162 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) the amino acid sequence of SEQ ID NO:8 from amino acid 187 to amino acid 300;
- (c) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8 or the amino acid sequence of SEQ ID NO:8 from amino acid 187 to amino acid 300. In further preferred embodiments, the present invention provides a protein comprising a fragment of the

amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 153 to amino acid 162 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- 10 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 3003 to nucleotide 3137;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 3072 to nucleotide 3137;
- 15 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 2713 to nucleotide 3114;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535;
- 25 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- 30 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 3003 to nucleotide 3137; the nucleotide sequence of SEQ ID NO:9 from nucleotide 3072 to nucleotide 3137; the nucleotide sequence of SEQ ID NO:9 from nucleotide 2713 to nucleotide 3114; the nucleotide sequence of the full-length protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 17 to amino acid 26 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) the amino acid sequence of SEQ ID NO:10 from amino acid 1 to amino acid 37;
- (c) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence

of SEQ ID NO:10 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
5 NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 17 to amino acid 26 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 284 to nucleotide 1357;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
15 NO:11 from nucleotide 603 to nucleotide 1233;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the
20 cDNA insert of clone cz653_11 deposited under accession number ATCC 98535;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA
25 insert of clone cz653_11 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 284 to nucleotide 1357; the nucleotide sequence of SEQ ID NO:11 from nucleotide 603 to nucleotide 1233; the nucleotide sequence of the full-length protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cz653_11 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 147 to amino acid 358. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO:12.
- Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 147 to amino acid 358;
- (c) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cz653_11 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence of SEQ ID NO:12 from amino acid 147 to amino acid 358. In further preferred

embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of 5 SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 10 NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 621 to nucleotide 1763;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1461 to nucleotide 1763;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;
- 20 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(i) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 621 to nucleotide 1763; the nucleotide sequence of SEQ ID NO:13 from nucleotide 1461 to nucleotide 1763; the nucleotide sequence of the full-length protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14 from amino acid 83 to amino acid 229. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 185 to amino acid 194 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 25 (a) the amino acid sequence of SEQ ID NO:14;
- (b) the amino acid sequence of SEQ ID NO:14 from amino acid 83 to amino acid 229;
- (c) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and
- 30 (d) the amino acid sequence encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14 or the amino acid sequence of SEQ ID NO:14 from amino acid 83 to amino acid 229. In further preferred

embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of 5 SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 185 to amino acid 194 of SEQ ID NO:14.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 10 NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 119 to nucleotide 295;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 191 to nucleotide 295;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone jj167_5 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone jj167_5 deposited under accession number ATCC 98535;
- 20 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone jj167_5 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone jj167_5 deposited under accession number ATCC 98535;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 119 to nucleotide 295; the nucleotide sequence of SEQ ID NO:15 from nucleotide 191 to nucleotide 295; the nucleotide sequence of the full-length protein coding sequence of clone ij167_5 deposited under accession number ATCC 98535; or the nucleotide sequence of a mature protein coding sequence of clone ij167_5 deposited under accession number ATCC 98535. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ij167_5 deposited under accession number ATCC 98535. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 26. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 25 (a) the amino acid sequence of SEQ ID NO:16;
- (b) the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 26;
- (c) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (d) the amino acid sequence encoded by the cDNA insert of clone ij167_5 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16 or the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 26. In further preferred embodiments,

the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 5 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:16.

- In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.
- 10 Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such
15 polynucleotide compositions in a suitable culture medium; and
(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a
20 pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a
25 pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

30

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide

sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by 5 expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host 10 cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

15

Clone "bn97_1"

A polynucleotide of the present invention has been identified as clone "bn97_1". bn97_1 was isolated from a human adult placenta cDNA library was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the 20 amino acid sequence of the encoded protein. bn97_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bn97_1 protein").

The nucleotide sequence of bn97_1 as presently determined is reported in SEQ ID NO:1. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bn97_1 protein corresponding to the foregoing nucleotide 25 sequence is reported in SEQ ID NO:2. Amino acids 55 to 67 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 68, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bn97_1 should be approximately 1700 bp.

30 The nucleotide sequence disclosed herein for bn97_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bn97_1 demonstrated at least some identity with sequences identified as AA046689 (zk72h06.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 488411 3'), D30934 (Human fetal-lung cDNA 5'-end sequence), R78820 (yi90b03.r1

Homo sapiens cDNA clone 146477 5'), and R91687 (yq10h09.s1 Homo sapiens cDNA clone 196577 3'). The predicted amino acid sequence disclosed herein for bn97_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bn97_1 protein demonstrated at least some 5 identity with sequences identified as A10431 (Hepatitis-B virus surface antigen P31). The bn97_1 protein also shows some identity (30% identity, 50% conserved amino acids) to both bovine and human lectin-like receptor for oxidized LDL (low-density lipoprotein). While this homology is weak, it gets stronger (44% identity and 62% conserved amino acids) in the lectin-like domain. Further, the 3' untranslated region of the bovine receptor 10 has seven mRNA unstabilising sequences (ATTTA) and bn97_1 has four in its 3' untranslated region. This lectin-like receptor for oxidized LDL (designated LOX-1, Sawamura *et al.*, 1997, *Nature* 386: 73-77) is an integral membrane protein which binds oxidized low-density lipoproteins, internalizes them into the endothelial cells and destroys them, thus playing a crucial role in the pathogenesis of atherosclerosis. Based 15 upon identity, bn97_1 proteins and each identical protein or peptide may share at least some activity.

Clone "bn268_11"

A polynucleotide of the present invention has been identified as clone "bn268_11". 20 bn268_11 was isolated from a human adult placenta cDNA library was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bn268_11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bn268_11 protein").

25 The nucleotide sequence of bn268_11 as presently determined is reported in SEQ ID NO:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bn268_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 30 bn268_11 should be approximately 1050 bp.

The nucleotide sequence disclosed herein for bn268_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bn268_11 demonstrated at least some identity with sequences

identified as D62832 (Human aorta cDNA 5'-end GEN-330C09) and U20159 (Mus musculus 76 kDa tyrosine phosphoprotein SLP-76 mRNA, complete cds). The predicted amino acid sequence disclosed herein for bn268_11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The 5 predicted bn268_11 protein demonstrated at least some identity with sequences identified as D83171 (GDP-GTP exchange protein for Rho1p [Saccharomyces cerevisiae]). Based upon identity, bn268_11 proteins and each identical protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the bn268_11 protein sequence centered around amino acid 33 of SEQ ID 10 NO:4; this region may also function as a signal sequence.

Clone "cb96_10"

A polynucleotide of the present invention has been identified as clone "cb96_10". cb96_10 was isolated from a human fetal brain cDNA library was identified as encoding 15 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cb96_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cb96_10 protein").

The nucleotide sequence of cb96_10 as presently determined is reported in SEQ ID NO:5. What applicants presently believe to be the proper reading frame and the 20 predicted amino acid sequence of the cb96_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 74 to 86 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 87, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 25 cb96_10 should be approximately 2100 bp.

The nucleotide sequence disclosed herein for cb96_10 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cb96_10 demonstrated at least some identity with sequences identified as AA459012, AA459236, AA256744 (zs31h11.r1 Soares NbHTGBC Homo 30 sapiens cDNA clone 686853 5'), N54489 (yv40f07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 245221 3'), and N57339 (yw81h07.r1 Homo sapiens cDNA clone 258685 5'). The predicted amino acid sequence disclosed herein for cb96_10 was searched against the GenPept and GeneSeq amino acid sequence databases using the

BLASTX search protocol. The predicted cb96_10 protein demonstrated at least some identity with sequences identified as X80036 (ascorbate peroxidase [Arabidopsis thaliana]). Based upon identity, cb96_10 proteins and each identical protein or peptide may share at least some activity. The TopPredII computer program predicts seven potential transmembrane domains within the cb96_10 protein sequence, centered around amino acid residues 25, 80, 125, 225, 300, 350, and 440 of SEQ ID NO:6. Therefore, cb96_10 is likely to be an integral membrane protein with multiple helices in the membrane; it also contains the sequence motif of the actinin-type actin-binding domains that are believed to anchor actin to the cell membrane.

10

Clone "cb213_11"

A polynucleotide of the present invention has been identified as clone "cb213_11". cb213_11 was isolated from a human fetal brain cDNA library was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cb213_11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cb213_11 protein").

The nucleotide sequence of cb213_11 as presently determined is reported in SEQ ID NO:7. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cb213_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 29 to 41 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 42, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cb213_11 should be approximately 2400 bp.

25 The nucleotide sequence disclosed herein for cb213_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cb213_11 demonstrated at least some identity with sequences identified as AA332165 (EST36344 Embryo, 8 week I Homo sapiens cDNA 5' end) and R34507 (g58a03.r1 Homo sapiens cDNA clone 36801 5'). The predicted amino acid 30 sequence disclosed herein for cb213_11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted cb213_11 protein demonstrated at least some identity with sequences identified as U39847

(AO13 ankyrin [Caenorhabditis elegans]). Based upon identity, cb213_11 proteins and each identical protein or peptide may share at least some activity.

Clone "cj457_4"

- 5 A polynucleotide of the present invention has been identified as clone "cj457_4".
cj457_4 was isolated from a human fetal brain cDNA library was identified as encoding
a secreted or transmembrane protein on the basis of computer analysis of the amino acid
sequence of the encoded protein. cj457_4 is a full-length clone, including the entire coding
sequence of a secreted protein (also referred to herein as "cj457_4 protein").
10 The nucleotide sequence of cj457_4 as presently determined is reported in SEQ ID
NO:9. What applicants presently believe to be the proper reading frame and the predicted
amino acid sequence of the cj457_4 protein corresponding to the foregoing nucleotide
sequence is reported in SEQ ID NO:10. Amino acids 11 to 23 are a predicted leader/signal
sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or
15 are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
cj457_4 should be approximately 3350 bp.

- 16 The nucleotide sequence disclosed herein for cj457_4 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
20 FASTA search protocols. cj457_4 demonstrated at least some identity with sequences
identified as T92881 (ye22a10.s1 Homo sapiens cDNA clone 118458 3') and T92488
(ye21g09.r1 Homo sapiens cDNA clone 118432 5'). Based upon identity, cj457_4 proteins
and each identical protein or peptide may share at least some activity. The TopPredII
computer program predicts a potential transmembrane domain within the cj457_4 protein
25 sequence, centered around amino acid 17 of SEQ ID NO:10; this region may also function
as a signal sequence.

Clone "cz653_11"

- A polynucleotide of the present invention has been identified as clone "cz653_11".
30 cz653_11 was isolated from a human adult testes cDNA library was identified as encoding
a secreted or transmembrane protein on the basis of computer analysis of the amino acid
sequence of the encoded protein. cz653_11 is a full-length clone, including the entire
coding sequence of a secreted protein (also referred to herein as "cz653_11 protein").

The nucleotide sequence of cz653_11 as presently determined is reported in SEQ ID NO:11. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cz653_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.

- 5 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cz653_11 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for cz653_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cz653_11 demonstrated at least some identity with sequences 10 identified as AA024740 (ze76c09.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 364912 3'), AA203204 (zx57b04.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 446575 5' similar to contains element MSR1 repetitive element), W72894 (zd59e06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344962 3'), and W76099 (zd59e06.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 15 344962 5'). The predicted cz653_11 demonstrated similarity to various WD-40 repeat containing proteins such as beta transducin-like protein (L28125) and coatomer, beta-prime subunit (AJ006523). The homology appears to be due to the presence of the Beta-transducin family Trp-Asp repeats signature (WD-40) beginning at residue 262 of SEQ ID NO:12. The WD-40 repeat has been thought to be a protein-protein interaction 20 domain. Based upon identity, cz653_11 proteins and each identical protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the cz653_11 protein sequence centered around amino acid 200 of SEQ ID NO:12.

- 25 Clone "dx138_4"

A polynucleotide of the present invention has been identified as clone "dx138_4". dx138_4 was isolated from a human adult testes cDNA library was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dx138_4 is a full-length clone, including the entire 30 coding sequence of a secreted protein (also referred to herein as "dx138_4 protein").

The nucleotide sequence of dx138_4 as presently determined is reported in SEQ ID NO:13. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dx138_4 protein corresponding to the foregoing

nucleotide sequence is reported in SEQ ID NO:14. Amino acids 268 to 280 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 281, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 5 dx138_4 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for dx138_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dx138_4 demonstrated at least some identity with sequences identified as AA108970 (ml63a06.r1 Stratagene mouse testis (#937308) Mus musculus 10 cDNA clone 516658 5'), AA280976 (zs97f01.r1 Soares NbHTGBC Homo sapiens cDNA clone 711577 5' similar to contains Alu repetitive element), H99316 (yx23a03.s1 Homo sapiens cDNA clone 262540 3'), T36050 (EST96120 Homo sapiens cDNA 5'), X85637 (H.sapiens mRNA for expressed sequence tag, clone CAM tEST417 (A)), and Z22280 (H.sapiens DNA sequence). Based upon identity, dx138_4 proteins and each identical 15 protein or peptide may share at least some activity.

Clone "ij167_5"

A polynucleotide of the present invention has been identified as clone "ij167_5". ij167_5 was isolated from a human adult blood (peripheral blood mononuclear cells treated 20 *in vivo* with G-CSF) cDNA library was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ij167_5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ij167_5 protein").

The nucleotide sequence of ij167_5 as presently determined is reported in SEQ ID 25 NO:15. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ij167_5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 12 to 24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 25, or are a transmembrane domain.

30 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ij167_5 should be approximately 1050 bp.

The nucleotide sequence disclosed herein for ij167_5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

FASTA search protocols. ij167_5 demonstrated at least some identity with sequences identified as N71115 (za87h10.s1 Homo sapiens cDNA clone 299587 3'), T85491 (yd78b01.r1 Homo sapiens cDNA clone 114313 5'), W04374 (za43f06.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 295331 5'), W05476 (za87h10.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 299587 5'), and W40146 (zb74d09.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 309329 5'). The predicted amino acid sequence disclosed herein for ij167_5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ij167_5 protein demonstrated at least some identity with sequences identified as M96653 (adenylyl cyclase, type 6 [Mus musculus]). Based upon identity, ij167_5 proteins and each identical protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ij167_5 protein sequence, centered around amino acid 40 of SEQ ID NO:16.

15 Deposit of Clones

Clones bn97_1, bn268_11, cb96_10, cb213_11, cj457_4, cz653_11, dx138_4, and ij167_5 were deposited on September 4, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98535, from 20 which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in this 25 composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate 30 cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* **19**: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* **9**: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped"

(i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the 5 vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences 10 provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
15	bn97_1	SEQ ID NO:17
	bn268_11	SEQ ID NO:18
	cb96_10	SEQ ID NO:19
	cb213_11	SEQ ID NO:20
	cj457_4	SEQ ID NO:21
20	cz653_11	SEQ ID NO:22
	dx138_4	SEQ ID NO:23
	ij167_5	SEQ ID NO:24

In the sequences listed above which include an N at position 2, that position is occupied 25 in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these 30 parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with g-³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 µl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 µg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately

labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to 5 particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology 10 Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The 15 desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have 20 multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce 25 gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation 30 can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988,

Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for 5 the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part 10 or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with 15 amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and 20 identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

25 In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., *Methods in Enzymology* 266: 460-480; Altschul et al., 1990, Basic local alignment search tool, *Journal of 30 Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by

reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is 5 copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and 10 selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue 15 penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps.

20 The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence 25 identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide 30 sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species

homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien et al., 1993, *Nature Genetics* 3:103-112; Johansson et al., 1995, *Genomics* 25: 682-690; Lyons et al., 1997, *Nature Genetics* 15: 47-56; O'Brien et al., 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 20 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and 25 screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly 30 stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as

stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) ^f	Hybridization Temperature and Buffer ^f	Wash Temperature and Buffer ^f
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T _B *; 1xSSC	T _B *; 1xSSC
	C	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	<50	T _D *; 1xSSC	T _D *; 1xSSC
	E	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
10	F	<50	T _F *; 1xSSC	T _F *; 1xSSC
	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T _H *; 4xSSC	T _H *; 4xSSC
	I	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T _J *; 4xSSC	T _J *; 4xSSC
15	K	RNA:DNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide
	L	RNA:RNA	<50	T _L *; 2xSSC
	M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide
	N	DNA:DNA	<50	T _N *; 6xSSC
	O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide
20	P	DNA:RNA	<50	T _P *; 6xSSC
	Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide
	R	RNA:RNA	<50	T _R *; 4xSSC

^f: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

^g: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

^{*T_B - T_R}: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G +

C bases). For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - (600/N)$, where N is the number of bases in the hybrid, and $[\text{Na}^+]$ is the concentration of sodium ions in the hybridization buffer ($[\text{Na}^+]$ for 1xSSC = 0.165 M).

5 Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

10 Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes,

15 where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in
20 Kaufman et al., *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control
25 sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster
30 Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and

Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

5 Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus
10 purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the
15 protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational
20 characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid
25 sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For
30 example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the 5 present invention.

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit 10 one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

15

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for 20 tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as 25 probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA 30 immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad.*

Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

25 Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors 5 discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, 10 MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those 15 described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 20 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. 25 Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine 30 Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; DeVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in*

- Immunology.* J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology.* J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;
- 5 Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology.* J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

20 A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well

25 as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses,

30 herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, 5 myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present 10 invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T 15 cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to 20 the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing 25 high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys 30 the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the

molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to 5 anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

10 The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as 15 described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

20 Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. 25 Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from 30 the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and

murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.

- 5 Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B
10 lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in*
15 *vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a
20 costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present
25 invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The
30 transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary

costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a 5 cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated 10 immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated 15 immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without 20 limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., 25 J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., 30 Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro*

antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, 5 those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnoli et al., *J. Immunol.* 149:3778-3783, 1992.

10 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., *J. Immunol.* 134:536-544, 1995; Inaba et al., *Journal of Experimental Medicine* 173:549-559, 1991; Macatonia et al., *Journal of Immunology* 154:5071-5079, 1995; Porgador et al., *Journal of Experimental Medicine* 182:255-260, 1995; 15 Nair et al., *Journal of Virology* 67:4062-4069, 1993; Huang et al., *Science* 264:961-965, 1994; Macatonia et al., *Journal of Experimental Medicine* 169:1255-1264, 1989; Bhardwaj et al., *Journal of Clinical Investigation* 94:797-807, 1994; and Inaba et al., *Journal of Experimental Medicine* 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, 20 proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., *Cytometry* 13:795-808, 1992; Gorczyca et al., *Leukemia* 7:659-670, 1993; Gorczyca et al., *Cancer Research* 53:1945-1951, 1993; Itoh et al., *Cell* 66:233-243, 1991; Zacharchuk, *Journal of Immunology* 145:4037-4045, 1990; Zamai et al., *Cytometry* 14:891-897, 1993; 25 Gorczyca et al., *International Journal of Oncology* 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., *Blood* 84:111-117, 1994; Fine et al., *Cellular Immunology* 155:111-122, 1994; Galy et al., *Blood* 85:2770-2778, 1995; Toki et al., *Proc. Nat. Acad Sci. USA* 88:7548-7551, 1991.

30

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell

lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and

Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

10

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in

circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

25 Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-

β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the 5 lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in:
Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et
10 al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc.
Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity
15 (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes,
fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell
population to a desired site of action. Chemotactic or chemokinetic proteins provide
particular advantages in treatment of wounds and other trauma to tissues, as well as in
20 treatment of localized infections. For example, attraction of lymphocytes, monocytes or
neutrophils to tumors or sites of infection may result in improved immune responses
against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it
can stimulate, directly or indirectly, the directed orientation or movement of such cell
25 population. Preferably, the protein or peptide has the ability to directly stimulate directed
movement of cells. Whether a particular protein has chemotactic activity for a population
of cells can be readily determined by employing such protein or peptide in any known
assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured
30 by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent
chemotaxis) consist of assays that measure the ability of a protein to induce the migration
of cells across a membrane as well as the ability of a protein to induce the adhesion of one
cell population to another cell population. Suitable assays for movement and adhesion

- include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. 5 APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

- A protein of the invention may also exhibit hemostatic or thrombolytic activity.
- 10 As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting 15 therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

- Assay for hemostatic and thrombolytic activity include, without limitation, those 20 described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

- 25 A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, 30 cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without

limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

- 5 Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987;
- 10 Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

Anti-Inflammatory Activity

- 15 Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or 20 suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin 25 lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human

diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved 5 extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only 10 itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with 15 polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion 20 suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

25 Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and 30 reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from

forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

5 Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present
10 invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities.
20 A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating
25 or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious
30 agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms;

effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress,
5 cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative
10 disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

15

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
20 Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of
25 the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF₀, TNF₁, TNF₂, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use
30 in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects

of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lyssolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active

ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a 5 therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, 10 lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with 15 cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or 20 cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical 25 composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils 30 may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein

of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100 mg (preferably about 0.1ng to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such

antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in

5 R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where

10 abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

30 The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and

polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other 5 ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

10 Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

15 A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic 20 acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells 25 are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor 30 (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of 5 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect 10 the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a 15 mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. 20 Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 69 to nucleotide 908;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 270 to nucleotide 908;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bn97_1 deposited under accession number ATCC 98535;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 83;
 - (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone bn97_1 deposited under accession number ATCC 98535;the protein being substantially free from other mammalian proteins.
8. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
9. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 83.
10. A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.
11. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.
12. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 562 to nucleotide 777;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 236 to nucleotide 673;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bn268_11 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bn268_11 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 37;

(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
(d) the amino acid sequence encoded by the cDNA insert of clone bn268_11 deposited under accession number ATCC 98535;
the protein being substantially free from other mammalian proteins.

14. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.

15. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 286 to nucleotide 1686;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 544 to nucleotide 1686;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 365 to nucleotide 1160;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cb96_10 deposited under accession number ATCC 98535;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

16. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 28 to amino acid 395;
- (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cb96_10 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins.

17. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:5.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 99 to nucleotide 1049;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 222 to nucleotide 1049;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 632 to nucleotide 998;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cb213_11 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) the amino acid sequence of SEQ ID NO:8 from amino acid 187 to amino acid 300;
- (c) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cb213_11 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins.

20. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:7.

21. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 3003 to nucleotide 3137;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 3072 to nucleotide 3137;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 2713 to nucleotide 3114;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cj457_4 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

22. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) the amino acid sequence of SEQ ID NO:10 from amino acid 1 to amino acid 37;

- (c) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cj457_4 deposited under accession number ATCC 98535;
the protein being substantially free from other mammalian proteins.
23. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.
24. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 284 to nucleotide 1357;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 603 to nucleotide 1233;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cz653_11 deposited under accession number ATCC 98535;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cz653_11 deposited under accession number ATCC 98535;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cz653_11 deposited under accession number ATCC 98535;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 147 to amino acid 358;
- (c) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
- (d) the amino acid sequence encoded by the cDNA insert of clone cz653_11 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins.

26. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.

27. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 621 to nucleotide 1763;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1461 to nucleotide 1763;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dx138_4 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

28. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:14;

(b) the amino acid sequence of SEQ ID NO:14 from amino acid 83 to amino acid 229;

(c) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and

(d) the amino acid sequence encoded by the cDNA insert of clone dx138_4 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins.

29. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:13.

30. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 119 to nucleotide 295;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 191 to nucleotide 295;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ij167_5 deposited under accession number ATCC 98535;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ij167_5 deposited under accession number ATCC 98535;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ij167_5 deposited under accession number ATCC 98535;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ij167_5 deposited under accession number ATCC 98535;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).


31. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 26;
- (c) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (d) the amino acid sequence encoded by the cDNA insert of clone ij167_5 deposited under accession number ATCC 98535;

the protein being substantially free from other mammalian proteins.


32. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.

FIGURE 1A



1/2

FIGURE 1B



SEQUENCE LISTING

<110> Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Racie, Lisa A.
Evans, Cheryl
Merberg, David
Treacy, Maurice
Agostino, Michael J.
Spaulding, Vikki
Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> 6052A

<140>

<141>

<160> 24

<170> PatentIn Ver. 2.0

<210> 1

<211> 1776

<212> DNA

<213> Homo sapiens

<400> 1
 agtcacagt agccggcg 60
 gaatccagat gcaggc 120
 ccaccatgag cctgcattct 180
 cagagcacag ggctccctct 240
 gcttgggtct gctgataggg 300
 tctccaatac tggtaagac 360
 aagagttgca atctttcaa 420
 ctgaaaaact ctgtcgtag 480
 cagaacaatg gaaatggcat 540
 gggaggactg taaatatttc 600
 aagaagacct ggaatttgcc 660
 cagggctttt gcgcctgac 720
 cttctgaact gtccattat 780
 ccatcttaa tggatgatc 840
 agagaaggc agaatgg 900
 aaggtgacty attgcctc 960
 caagggctag ttgagacatt 1020
 agtacaaaat gggttcgt 1080
 tatgcacgtt ttaacagtc 1140
 accataatg tcatctgcct 1200
 tgtctaatac cacctccctg 1260
 ttgaagtata gggaaatacat 1320
 agaaattggc agtcacttcc 1380
 gtttcagttc atactagtcc 1440
 tgccgttcc caacaggat 1500
 gcattccctc ctgtgtccat 1560
 ccagggaaaga aatatatccc 1620
 cttcaagagag attaaagacc 1680
 cagttccat tttcttccat 1740
 ataataaata gaaatactgt 1776

<210> 2
<211> 280
<212> PRT
<213> Homo sapiens

<400> 2
Met Gln Ala Lys Tyr Ser Ser Thr Arg Asp Met Leu Asp Asp Asp Gly
1 5 10 15
Asp Thr Thr Met Ser Leu His Ser Gln Ala Ser Ala Thr Thr Arg His
20 25 30
Pro Glu Pro Arg Arg Thr Glu His Arg Ala Pro Ser Ser Thr Trp Arg
35 40 45
Pro Val Ala Leu Thr Leu Leu Thr Leu Cys Leu Val Leu Leu Ile Gly
50 55 60
Leu Ala Ala Leu Gly Leu Leu Phe Phe Gln Tyr Tyr Gln Leu Ser Asn
65 70 75 80
Thr Gly Gln Asp Thr Ile Ser Gln Met Glu Glu Arg Leu Gly Asn Thr
85 90 95
Ser Gln Glu Leu Gln Ser Leu Gln Val Gln Asn Ile Lys Leu Ala Gly
100 105 110
Ser Leu Gln His Val Ala Glu Lys Leu Cys Arg Glu Leu Tyr Asn Lys
115 120 125
Ala Gly Ala His Arg Cys Ser Pro Cys Thr Glu Gln Trp Lys Trp His
130 135 140
Gly Asp Asn Cys Tyr Gln Phe Tyr Lys Asp Ser Lys Ser Trp Glu Asp
145 150 155 160
Cys Lys Tyr Phe Cys Leu Ser Glu Asn Ser Thr Met Leu Lys Ile Asn
165 170 175
Lys Gln Glu Asp Leu Glu Phe Ala Ala Ser Gln Ser Tyr Ser Glu Phe
180 185 190
Phe Tyr Ser Tyr Trp Thr Gly Leu Leu Arg Pro Asp Ser Gly Lys Ala
195 200 205
Trp Leu Trp Met Asp Gly Thr Pro Phe Thr Ser Glu Leu Phe His Ile
210 215 220
Ile Ile Asp Val Thr Ser Pro Arg Ser Arg Asp Cys Val Ala Ile Leu
225 230 235 240
Asn Gly Met Ile Phe Ser Lys Asp Cys Lys Glu Leu Lys Arg Cys Val
245 250 255
Cys Glu Arg Arg Ala Gly Met Val Lys Pro Glu Ser Leu His Val Pro
260 265 270
Pro Glu Thr Leu Gly Glu Gly Asp
275 280

<210> 3
<211> 947
<212> DNA
<213> Homo sapiens

<400> 3
caactatccc ataatttatt tattcttctt caatgtttgt aaagtgcatt agtcattgttc 60
acacttgaag tcttagtagtg cactgtaata attcattttt taaaagatta tttaatgcc 120
atttcaaaat acagtagttt acacagctac agaaaacaatt tggggcaagt tttaaaacac 180
tgaaaacaga atagtttattg gtgtcacata aaactgattt gtttttaca gccaaacctc 240
tgtcagtcag aggcattcat tagtttata catgtaattt gaaaatcaact aaacctcggt 300
ttctcagcg caataattta agaggcttca aaaatataat ttcaacttta tttagtattt 360
tttcctgggg ggatttttac gtaattttt tatgaaaaaa caaatgcattt ttgagataac 420
ttctgggatt aaaatagtc tttgcttac tttttttttt tcctaaaaca actttattga 480
cttttagtcc atactgttat atttttgtct taaaagaaaat taaaactaca aatacaaaaa 540
gaaaacattt taaatttagg gatgagactt tggtgtatcg tgggtctagg tttaatgaac 600
acatctgggg ttaagttggc atttcttcac atctccacac ccacaccaac catcacagcc 660
ccccaccaac ctctcccaa ccccaaaaggc atttccagg gatatacattt ttaccaaagg 720
cttcctggga agacgaggga gcaacacttt agattaaatg tgatcagact ttccatttt 780
atatggctct tctgtcttctt gttatcccc tgacagctt gccataaagt ccctcttctt 840
catccctccc aaacaggctg tataagtgtt ttgaggtat taaactctt cctccagttt 900
acaaatatca cttacaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 947

<210> 4
<211> 72
<212> PRT
<213> Homo sapiens

<400> 4
Met Arg Leu Trp Cys Ile Val Gly Leu Gly Leu Met Asn Thr Ser Gly
1 5 10 15
Val Lys Leu Ala Phe Leu His Ile Ser Thr Pro Thr Pro Thr Ile Thr
20 25 30
Ala Pro His Gln Pro Ser Pro Asn Pro Lys Ser Ile Val Gln Gly Tyr
35 40 45
Arg Phe Tyr Gln Arg Leu Pro Gly Lys Thr Arg Glu Gln His Phe Arg
50 55 60
Leu Asn Val Ile Arg Leu Ser Tyr
65 70

<210> 5
<211> 2120
<212> DNA
<213> Homo sapiens

<400> 5
cgctgacttg ggcaatgggg ccgggtgggt ttggggcgg aagagaccct cgggggtttag 60
aagtatgtgg tggcctttcg tccccgtaa aacattgtca cacgggtgtgg ggcggcagcg 120
ctggatctt gcaaggctat tttggcattc tgctggatat atgttctaa ataccaaagt 180
cggcggaaa gtgaagttgt ctccaccata acagcaattt tttctctagc aattgcactt 240
atcacatcag cacttctacc agtggatata tttttgggtt cttacatgaa aaatcaaaat 300
ggtacattta aggactgggc taatgtaat gtcagcagac agattgagga cactgtatta 360
tacggttact atactttata ttctgttata ttgttctgtg tggttctctg gatccctttt 420
gtctacttctt attatgaaga aaaggatgat gatgatacta gtaaatgtac tcaaattaaa 480

acggcactca agtatacttt gggatttgtt gtgatttgc cactgcttct tttagtttgt 540
 gcctttgttc cattgaatgt tcccaataac aaaaattcta cagagtggaa aaaagtgaag 600
 tccctatttg aagaacttgg aagttagtcat ggtagtgc cattgtcatt ttctatcagt 660
 tctctgacct tgatttggaaat gttggcagct ataaacttaca cagcctatgg catgtctgcg 720
 ttacctttaa atctgataaa aggcactaga agcgctgctt atgaacgtt gaaaaacact 780
 gaagacattg aagaagttaga acaacacatt caaacgatta aatcaaaaaag caaagatgg 840
 cgaccttgc cagcaaggaa taaacgcgcc taaaacaat ttgaagaaag gttacgaaca 900
 cttaagaaga gagagaggca tttagaattc attgaaaaca gctggtggac aaaaattttgt 960
 ggcgcctgc gtccttgc gatcgtctgg ggaatatttt tcatcttagt tgcattgctg 1020
 tttgttaattt ctcttttctt gtcaaattta gataaagctc ttcatcagc tggaatagat 1080
 tctggttca taattttgg agctaaccctg agtaatccac tgaatatgtc tttgcctta 1140
 ctacaaacag tttccctct tgattatatt ttataacaa ttatttattt gtactttatt 1200
 tttacttcaa tggcaggaat tcgaaatattt ggcataatgg tctttttgt tagatttat 1260
 aaaatcagaa gaggttagaac caggccccaa gcactcctt ttctctgc gataacttctg 1320
 cttattgtcc ttacacactag ctacatgatt tatagtctt ctccccata tggatgtat 1380
 ggaagccaaa attacttaat agagactaat ataacttctg ataatcataa aggcaattca 1440
 acccttctg tgccaaagag atgtgatgca gatgctcctg aagatcagt tactgttacc 1500
 cggacatacc tattccctca caagttctgg ttcttcagtg ctgcttacta ttttggtaac 1560
 tgggccttc tttgggtattt tttgatggaa ttaatttgc tctgttgcg aggaaagaaa 1620
 tcggttattt aaggagttaga tgaagattca gacataagt atgatgagcc ctctgtctat 1680
 tctgcttgcg acgccttctgt cttaaagggtt ttataatgtc gactgaatat ctgttatgca 1740
 tttttaaagt attaaactaa cattaggatt tgtaacttag ctttcatcaa aaatgggagc 1800
 atggctataa gacaactata ttttattata tttttctga agtaacattg tatcatagat 1860
 taacattta aattaccata atcatgctat gtaaaatataa gactactggc ttttgaggg 1920
 aatgttgcg caaaattttt tcctctaattg tataatgtc taaaatttgc taaaatctt 1980
 ccagaattaa tattccctt tgcactttt tgaaaacata ataaatcatt tgcattctgt 2040
 ccttaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100
 aaaaaaaaaa aaaaaaaaaa 2120

<210> 6
 <211> 467
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Lys Asn Gln Asn Gly Thr Phe Lys Asp Trp Ala Asn Ala Asn Val
 1 5 10 15

Ser Arg Gln Ile Glu Asp Thr Val Leu Tyr Gly Tyr Tyr Thr Leu Tyr
 20 25 30

Ser Val Ile Leu Phe Cys Val Phe Phe Trp Ile Pro Phe Val Tyr Phe
 35 40 45

Tyr Tyr Glu Glu Lys Asp Asp Asp Asp Thr Ser Lys Cys Thr Gln Ile
 50 55 60

Lys Thr Ala Leu Lys Tyr Thr Leu Gly Phe Val Val Ile Cys Ala Leu
 65 70 75 80

Leu Leu Leu Val Gly Ala Phe Val Pro Leu Asn Val Pro Asn Asn Lys
 85 90 95

Asn Ser Thr Glu Trp Glu Lys Val Lys Ser Leu Phe Glu Glu Leu Gly
 100 105 110

Ser Ser His Gly Leu Ala Ala Leu Ser Phe Ser Ile Ser Ser Leu Thr
 115 120 125

Leu Ile Gly Met Leu Ala Ala Ile Thr Tyr Thr Ala Tyr Gly Met Ser

130	135	140
Ala Leu Pro Leu Asn Leu Ile Lys Gly Thr Arg Ser Ala Ala Tyr Glu		
145	150	155
Arg Leu Glu Asn Thr Glu Asp Ile Glu Glu Val Glu Gln His Ile Gln		
165	170	175
Thr Ile Lys Ser Lys Ser Lys Asp Gly Arg Pro Leu Pro Ala Arg Asp		
180	185	190
Lys Arg Ala Leu Lys Gln Phe Glu Glu Arg Leu Arg Thr Leu Lys Lys		
195	200	205
Arg Glu Arg His Leu Glu Phe Ile Glu Asn Ser Trp Trp Thr Lys Phe		
210	215	220
Cys Gly Ala Leu Arg Pro Leu Lys Ile Val Trp Gly Ile Phe Phe Ile		
225	230	235
Leu Val Ala Leu Leu Phe Val Ile Ser Leu Phe Leu Ser Asn Leu Asp		
245	250	255
Lys Ala Leu His Ser Ala Gly Ile Asp Ser Gly Phe Ile Ile Phe Gly		
260	265	270
Ala Asn Leu Ser Asn Pro Leu Asn Met Leu Leu Pro Leu Leu Gln Thr		
275	280	285
Val Phe Pro Leu Asp Tyr Ile Leu Ile Thr Ile Ile Met Tyr Phe		
290	295	300
Ile Phe Thr Ser Met Ala Gly Ile Arg Asn Ile Gly Ile Trp Phe Phe		
305	310	315
Trp Ile Arg Leu Tyr Lys Ile Arg Arg Gly Arg Thr Arg Pro Gln Ala		
325	330	335
Leu Leu Phe Leu Cys Met Ile Leu Leu Ile Val Leu His Thr Ser		
340	345	350
Tyr Met Ile Tyr Ser Leu Ala Pro Gln Tyr Val Met Tyr Gly Ser Gln		
355	360	365
Asn Tyr Leu Ile Glu Thr Asn Ile Thr Ser Asp Asn His Lys Gly Asn		
370	375	380
Ser Thr Leu Ser Val Pro Lys Arg Cys Asp Ala Asp Ala Pro Glu Asp		
385	390	395
Gln Cys Thr Val Thr Arg Thr Tyr Leu Phe Leu His Lys Phe Trp Phe		
405	410	415
Phe Ser Ala Ala Tyr Tyr Phe Gly Asn Trp Ala Phe Leu Gly Val Phe		
420	425	430
Leu Ile Gly Leu Ile Val Ser Cys Cys Lys Gly Lys Lys Ser Val Ile		
435	440	445
Glu Gly Val Asp Glu Asp Ser Asp Ile Ser Asp Asp Glu Pro Ser Val		

450

455

460

Tyr Ser Ala
465

<210> 7
<211> 2487
<212> DNA
<213> Homo sapiens

<400> 7
gttccgaaat aaaagatttt gcaaaccact ttccctacgta cgtccactgt agttttgca 60
gataacaac tagctgttagc aaagcctatg taaaatcatat gatgagctt catagtaacc 120
gtccaagcaa aaggttttgt attttaaga agcattcaga aaatctccgg ggcattactc 180
tagtgtgcct taattgtat ttccctaagt atgtttctgg cttagataat atggctacac 240
acttaagtca acataaaaact catacttgcc aagttgtaat gcagaaaagt tctgtttgta 300
tccccacttc tgagcacctt tctgaattaa aaaaagaagc tccccgaaag gaacaagaac 360
ctgtgtctaa gggaaattgca agacctaaca tggtctgaaag agaaaacagaa acatcaaatt 420
ctgaaagtaa acaagataaa gctgcttctt caaaagaaaa aaatggatgt aatgcaaatt 480
catttgaagg ctcatcaaca acaaaaaagt aagaaagcat aacagtttca gataaggaaa 540
atgaaaacctg tcttgcagac cagggaaactg gctcaaaaaa catcgctagt tgtgattcaa 600
atattgggtc agataaaagt gaaaagaaaa aacaaataca acacgtttgt cagggaaatgg 660
agttgaagat gtgccaaagt tcagaaaaca taatcttatac tgatcagatt aaagatcaca 720
actccagtga agccagattt tcttcaaaaatgaa atattaagga tttgcgattt gcatcagata 780
atgtaagcat tgatcagttt ttgagaaaaa gacatgaaacc tgaatctgtt agttctgtg 840
ttagcgagca aggcagtatt catttggAAC ctctgactcc atccggaggtt cttgagttt 900
aagccacaga gattcttcag aaaggtagt gttttttttt agccaaagact gatgaagtag 960
tgtctgtatca aacagatgac attcttggag gaaaataaccc tagcacaaca gaggcaacag 1020
tagacctgga agatgaaaaa gaaagaagtt gaaatttagtc attttaagtt tcagtgttacc 1080
aacgataagg gcatttggaa cagtgcatac aggtgagctc agtgggtgtt ttgttaggtt 1140
agaaatggaa atatgtttagg gaggtcacac atacacttta cctgtatgtt caacctatgt 1200
tatcaaaacaa atcaatttac caataatagc atgatttagta gggattccca aaaagttttt 1260
aaaaacacga acaggatttt aatgataatt aaatttgcag tggaaagtc tcatttaatg 1320
gttttcaagg aaatgggatt tggttgttca catgaaatttga tgatattttt aatatttata 1380
aagccttca aacttccatc aatcctaagc taaaatctt tattacctgt atatcctttt 1440
cagtttaactg agaggaaggg atttggaaac catgtacttt tggggagttt ttgattaaaa 1500
acaatggctg attggcattt ttaatgttgg ctttttttt gaggatgtt ctggtaaatg 1560
gagcatgctt agagtactaa attgtatctt tgagaattttt gatgaacata aactttaattt 1620
tggatttaat ataacattcc agtcagacgc atgtttttttt aatatttggaa tctttgttacc 1680
tccatacaag ttttagctgtt ccaggctgtt agcttacctt aattttttt tcagtgttacc 1740
tggattttt aagatataaa tttttttttt tgctttttt cagtgttca gctgtgttacc 1800
aattcttca tgatattttt gtattttttt aagttttttt cccattttt gaaacttctgt 1860
agctattttt tttttttttt tttttttttt gaaatggcc cataaaaaatg 1920
gtctgttccca aacccaaatg tatggtataa tgtagatatt gtaaaggcagt aaactgaaaa 1980
catgttccgg catgttattca gccatgtttt agtgactttt ctgttattttt aaaaataaaa 2040
cttcaatgg gacctaaaac agtgatgtt aagaactggg tttggaaattt tagcttattt 2100
tatctataag atggctgttca aattttttttt tttttttttt ttatcatcttta gaatataata 2160
gatatagaaa tgaataatataa gaagaacagt agttttttttt gaaatactaa taaactttt 2220
ttttaatgttca ttcatatttt tttttttttt tgcttttttgg attttttttt ttttttttcc 2280
tgaatgttca atgtttttttt tggctttttt aatactctgtc tttttttttt gatgtttttttt 2340
taaatattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2400
aaaaaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa 2460
aaaaaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa 2487

<210> 8
<211> 317
<212> PRT
<213> Homo sapiens

<400> 8
 Met Met Ser Phe His Ser Asn Arg Pro Ser Lys Arg Phe Cys Ile Phe
 1 5 10 15
 Lys Lys His Ser Glu Asn Leu Arg Gly Ile Thr Leu Val Cys Leu Asn
 20 25 30
 Cys Asp Phe Leu Ser Asp Val Ser Gly Leu Asp Asn Met Ala Thr His
 35 40 45
 Leu Ser Gln His Lys Thr His Thr Cys Gln Val Val Met Gln Lys Val
 50 55 60
 Ser Val Cys Ile Pro Thr Ser Glu His Leu Ser Glu Leu Lys Lys Glu
 65 70 75 80
 Ala Pro Ala Lys Glu Gln Glu Pro Val Ser Lys Glu Ile Ala Arg Pro
 85 90 95
 Asn Met Ala Glu Arg Glu Thr Glu Thr Ser Asn Ser Glu Ser Lys Gln
 100 105 110
 Asp Lys Ala Ala Ser Ser Lys Glu Lys Asn Gly Cys Asn Ala Asn Ser
 115 120 125
 Phe Glu Gly Ser Ser Thr Thr Lys Ser Glu Glu Ser Ile Thr Val Ser
 130 135 140
 Asp Lys Glu Asn Glu Thr Cys Leu Ala Asp Gln Glu Thr Gly Ser Lys
 145 150 155 160
 Asn Ile Val Ser Cys Asp Ser Asn Ile Gly Ala Asp Lys Val Glu Lys
 165 170 175
 Lys Lys Gln Ile Gln His Val Cys Gln Glu Met Glu Leu Lys Met Cys
 180 185 190
 Gln Ser Ser Glu Asn Ile Ile Leu Ser Asp Gln Ile Lys Asp His Asn
 195 200 205
 Ser Ser Glu Ala Arg Phe Ser Ser Lys Asn Ile Lys Asp Leu Arg Leu
 210 215 220
 Ala Ser Asp Asn Val Ser Ile Asp Gln Phe Leu Arg Lys Arg His Glu
 225 230 235 240
 Pro Glu Ser Val Ser Ser Asp Val Ser Glu Gln Gly Ser Ile His Leu
 245 250 255
 Glu Pro Leu Thr Pro Ser Glu Val Leu Glu Tyr Glu Ala Thr Glu Ile
 260 265 270
 Leu Gln Lys Gly Ser Gly Asp Pro Ser Ala Lys Thr Asp Glu Val Val
 275 280 285
 Ser Asp Gln Thr Asp Asp Ile Pro Gly Gly Asn Asn Pro Ser Thr Thr
 290 295 300
 Glu Ala Thr Val Asp Leu Glu Asp Glu Lys Glu Arg Ser
 305 310 315

<210> 9
<211> 3495
<212> DNA
<213> *Homo sapiens*

<400> 9
tttatttttc aaatcataat tttaaaatga tagataccat tttgtgataa caacaattca 60
gaaaacaatt ttctatcctc tttagttaaaa gaatgttagt acagtttggaa tacttgtact 120
ttaattttag agtaaacatc tgccattatac tcttatacat aatagaatta tttagttaag 180
aaattctta cagtaaatga gataatgtgt gaaaaaggat tttgtaaatg ctgaggattc 240
tacaaatgtat agttgttatt ttcatgtgtt tttgtaaatg catgtccatt tcataat 300
aggacttcac ataaaaaaaaa actttctcaa gacaacttta tattctagta tttttctgtt 360
gtaaaaagta ttaactatc acttttattt tggtatacat ttatTTTaaat atccatgtgt 420
ttattatagt aaatttgaaa tgaatcccg aaaaacagaa tttttttaaa cacagacctc 480
acaccaatata taatttttc tctacataat tttaaaactac ataaattaag tactttaaaat 540
ttatattgaa ggcaccaag aacttaggtt gaatcttga aaatttaaaat aactatTTT 600
aaagttaccc aacttaatata tttatTTTaaat taatatttat ctcccttac taattcttga 660
taaataatag cattagactt gataaaaataa aaaaagaattt tagagttagaa ttaatataatc 720
aaaaggggta tatcaaccaa attgggtgtca gattgtattt attctctat cacataaaga 780
tttttctttt gataggtgt gctcatatga acctttgggt tagaatctat atatgtacat 840
gtgtatgtat gtagatgtat tggtgtata cacacatata tacccaaacac catgaatttt 900
agcagtctgt gatgatcagc aaaaagcac ataaagtaaa attagttgac catgtaaat 960
tcaattctgg aattttttttt tattttggca tttctagaac tttttacatt tgaatgtaca 1020
tgatgagat tagtaacat gacttatgtt taatcagaat cttaatgaca atttagttt 1080
acaaggctcag aagagatgag tttgctaaac ccagctgtga tacctcagtt gaaaaggaa 1140
ttcaaaaggta tgctttgttag aacagaaaaag tataatTTTttt ttttcatgaa cttaatcat 1200
tttctgtttt tcctctatgt gagtcagcta caaaagtggg ctaatTTTaaat caacagtaga 1260
acttccctct tttctactgt aatcttccca ctgactttac tgacaggtt tgaatataacta 1320
gtgtatttgg tcttcagtaa cctttttatt tccttagatga ttgaaatataa ggtattttact 1380
ccatTTTaaac cagggtgataa gatgtatgtt atactcaggg agggtattttt ctgttactt 1440
ttgctcgttt ggggtgtaaa gtggccatgac tgaataatct tcaattcatg attcttaggt 1500
aagttaattt tggaaaaaagg ggcttcacac atgggtgggg ttgaacatgtt attcttactt 1560
actttaaaag atggaaaatgt tttgtggact gatacatTTTttt atcttacttga atatgaattt 1620
tttatgtatc tctactgtca aatagcccc ttgaaactca gggaaagacaa aggttcaattt 1680
acaccacttt tgtaataag caaaccaggat atttttttt tctcctgttg tctggatatg 1740
gcaatagatt ttttaatttgc ctgtgagaac ccatatatgtt aagagagagga gttgaattgt 1800
gtgtgccttt tatgtcttga gatttatatg tggaaaagac gacatctact tcaaactgtt 1860
ttttttcgt tttttttttt tttttgggaa aggggggaga acggggcttt gctctgtcgc 1920
ccaggctggaa gtgcagtggc gcgatctcag ctgactgcaa cctccaccc tcgggttcaa 1980
gggattctgc ctcaagccccc cgagtagctg agaccacagg tgctgcccc cacacccggc 2040
taattttttt gtatTTTtag tagagacggg gtttagttaga gacggatcac tcctgaccac 2100
gtgatccgccc cacccctggcc tcccaaagtg ctgggattac aggcgttgagc caccaccccc 2160
ggcctgtatt ttcaagagagg agagcttggt gttttgtgg tgccaagtg taagataatg 2220
tctcttgag gcttcctatg gactgcctttt attttagtaa actcaagaca ccagtttacc 2280
tcaacagagt tttggcccta tttagatTTTttt ttgtgcattt tattgaaagc cagggttaca 2340
tcacccctcacc ccattattct ttttagttaa ataaatttac catgccaagt aaccagaatg 2400
gagcaaaattt gttgatcttt aaggcagtag gttgacttag ctagctatca ttattgtc 2460
atctaattgtt aggcaccaga aaccatttga gccaggagtg tgaatgaata attcccaagag 2520
acacttttaga cattttttaa tgttttatat gacattttac atttgtgttgc ttgcctttaga 2580
tattaaattt tccttagtgc gataaaaaaca gcaacattca taacttattt tataatTTTgt 2640
tccaaagaaaa agaatttggtt ttaatggttt caaaataact gcaccccttgc atttgtttagt 2700
gccttaagtt ctcttagtgc atttcaactt tttttcaat ctaaatgaag cttaatcccttgc 2760
ataagggtca tattttgttca ctatagatgta aataaaacttc cccttcttaa atttgcattt 2820
aagcaccaac gtgtgggtgc ttggcagaat gagaatgtt agggagattt ttggatgttt 2880
ggagtttcat tattttttt gtttttattt ttgtatTTTttt aggtgcattt taaaatattt 2940
agacaaaatata ctatcttaca ttgattaaac ccgtgtttt tttttttttt tttttttttt 3000
gaatgtcaaa aaagtataact tattttttttt ccatactttaat tttttttttt tttttttttt 3060
aggcttttttccattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 3120

cccaaggttt ctttatttaa attttatttg agagttgtt gactctaag acaataaaaa 3180
 tttagatgg aacaaaagta taatctgctt tacaactagt atagaccctaa ggtcatttgc 3240
 tttcaattag aggctccaga gtcttcatalog tgaaaagaat gctttgtatt taattgttct 3300
 tagttaaatgtt gtagcacgtg aataactact tacatgtttt gtttaaatat acttcttgca 3360
 tagtttaattttttaaatgtt gtagtatctat aaaaatgttctt ttaaccattta ttacttgact 3420
 atatggttgtt attaaatttt gtttacgaaa aaaaaaaaaa aaaaaaaaaa 3480
 aaaaaaaaaa aaaaa 3495

<210> 10
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Ser Lys Lys Tyr Thr Tyr Phe Cys Ser Ile Leu Met Tyr Asn Phe
 1 5 10 15
 Phe Pro Leu Gln Ala Phe Ser Phe Thr Phe Leu Lys Lys His Leu Leu
 20 25 30
 Ser Pro Ser Leu Ser Pro Leu Pro Gln Gly Phe Phe Ile
 35 40 45

<210> 11
 <211> 1398
 <212> DNA
 <213> Homo sapiens

<400> 11
 gttgatccat ctgagaaaagg gatcatgaac tagacagaat gaacagcctt agagggcacag 60
 actcttgaac gggacgggtgg tggatgact atgtcagagt gtttagagat cactcagttt 120
 ttaaaagactg gcctttatcg tgtctcagtg cagccgagggc agagcctttg aaggatgcga 180
 tgggtgcatt cttaactaattc tagtccagcc gctgaggtga ctttcaacggc cagaccgtct 240
 cctgagcggcc ccaggttagaa tttcaaaaatgtt cttccgggacc attatggcag tcaagtggac 300
 ggggtggcat tcttctcctg tcctctgcctt gaatgcagttt aaagaaggc tgctggcttc 360
 tggagcagag ggcggagatc tcacggctt gggtaagat ggaactccat taggacacac 420
 gcccgtccaa ggggctgtat atgttaccag tggatgtttt tctccctctt gtcccaccaa 480
 gctctatgcc tcacatggag aaaccatgtt tggatgttgc gtcaggccc tcaaagattc 540
 cttggaccat tttcatgtga atgaagaaga aatcaattgtt ctttcattga atcaaacgg 600
 aaacctgctg gcttctgctg acgactctgg gcaatcaaa atccttagact tggaaaacaa 660
 gaaaggatattc agatccttgc agagacattc caatatctgc tcctcagttt ctttcggcc 720
 tcagaggcctt cagacgcttgc tggatgttgc actggatattc caggtgtatc tggatgtt 780
 tcaaaaagcc cgaccactctt ggattacaaa ttacaggag gatgaaaacag aaaaaatgg 840
 aggccccacag tcacctggtc agctctttaa ccctggcccta gcccattcta tctctgtggc 900
 ttcgtgttgtt aatatttttta gttgtgttgc agaagatggt aaggttgc ttttcgggt 960
 gatgggagtt aagtgtgaac aggaactggg attaaggc cacacttcag gggatcccc 1020
 ggtctgtttt ctcccaaaaat cttttttttt gcttacttggaa gggatgtatc ggaatgtt 1080
 gttgtggat gcaaacatgtt aagtttggaa aaaacagaag agtcccacaa aacgttcccc 1140
 caggaagaaaa cttttttttt gttttttttt gggatgttgc aacgttcccc 1200
 aacagatggat gaaatggatc gcaacatccc accggatgtt aatatttttgc atggagaaaa 1260
 agtgaactgg ctcttgggtt caaaaataaa gggatgttgc aatatttttgc tggatgtt 1320
 aacttagttgtt atatctgtat accccctttaa tggatgttgc aatccatggaa 1380
 gaaaaaaaaa aaaaaaaaaa 1398

<210> 12
 <211> 358
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Ala Val Lys Trp Thr Gly Gly His Ser Ser Pro Val Leu Cys Leu
 1 5 10 15

Asn Ala Ser Lys Glu Gly Leu Leu Ala Ser Gly Ala Glu Gly Gly Asp
 20 25 30

Leu Thr Ala Trp Gly Glu Asp Gly Thr Pro Leu Gly His Thr Arg Phe
 35 40 45

Gln Gly Ala Asp Asp Val Thr Ser Val Leu Phe Ser Pro Ser Cys Pro
 50 55 60

Thr Lys Leu Tyr Ala Ser His Gly Glu Thr Ile Ser Val Leu Asp Val
 65 70 75 80

Arg Ser Leu Lys Asp Ser Leu Asp His Phe His Val Asn Glu Glu Glu
 85 90 95

Ile Asn Cys Leu Ser Leu Asn Gln Thr Glu Asn Leu Leu Ala Ser Ala
 100 105 110

Asp Asp Ser Gly Ala Ile Lys Ile Leu Asp Leu Glu Asn Lys Lys Val
 115 120 125

Ile Arg Ser Leu Lys Arg His Ser Asn Ile Cys Ser Ser Val Ala Phe
 130 135 140

Arg Pro Gln Arg Pro Gln Ser Leu Val Ser Cys Gly Leu Asp Met Gln
 145 150 155 160

Val Met Leu Trp Ser Leu Gln Lys Ala Arg Pro Leu Trp Ile Thr Asn
 165 170 175

Leu Gln Glu Asp Glu Thr Glu Glu Met Glu Gly Pro Gln Ser Pro Gly
 180 185 190

Gln Leu Leu Asn Pro Ala Leu Ala His Ser Ile Ser Val Ala Ser Cys
 195 200 205

Gly Asn Ile Phe Ser Cys Gly Ala Glu Asp Gly Lys Val Arg Ile Phe
 210 215 220

Arg Val Met Gly Val Lys Cys Glu Gln Glu Leu Gly Phe Lys Gly His
 225 230 235 240

Thr Ser Gly Val Ser Gln Val Cys Phe Leu Pro Glu Ser Tyr Leu Leu
 245 250 255

Leu Thr Gly Gly Asn Asp Gly Lys Ile Thr Leu Trp Asp Ala Asn Ser
 260 265 270

Glu Val Glu Lys Lys Gln Lys Ser Pro Thr Lys Arg Thr His Arg Lys
 275 280 285

Lys Pro Lys Arg Gly Thr Cys Thr Lys Gln Gly Gly Asn Thr Asn Ala
 290 295 300

Ser Val Thr Asp Glu Glu Glu His Gly Asn Ile Leu Pro Lys Leu Asn
 305 310 315 320

Ile Glu His Gly Glu Lys Val Asn Trp Leu Leu Gly Thr Lys Ile Lys
 325 330 335

Gly His Gln Asn Ile Leu Val Ala Asp Gln Thr Ser Cys Ile Ser Val
340 345 350

Tyr Pro Leu Asn Glu Phe
355

<210> 13
<211> 2132
<212> DNA
<213> *Homo sapiens*

<400> 13
ccggaggtag ctaccacggc ctgtgtcaac gactaaagct ccagtacagc ggcgcctca 60
gacagctggg agggtggc tcggccggag cggccggcgg tgagctaccg cgaggaggag 120
cgccggaggc gacctcgcc cggccctgca ctggccgccc ggcaggcgcg acatgaccc 180
ggtctggcat cgcgggatg ctccctaagc ccctctccg gctgttaacc tccgggaac 240
ggttgtgacc acaccgacac gtattttaca gataaatcat ttttcggcg gcgggtcgaa 300
cacgttatt tatttttat ttctcaaca agctttacc cagcacctgt ccagtaaaac 360
aacttgataa tcgttgcag gggcgtccgc cgggttagga agccactgcc tggcaacttg 420
tggaaagcctc atttgcaaag cccactca gatgtttga agatcgtgac gtcttgaac 480
tagcagtgta tgcacagaat cctactcaag gaacgtctt gcccagcgat gcaaagaact 540
gaagttca a gctggaagag cctgtattgt cctcacaata gtatagaaga attcaagaga 600
ggagagagag acagcaccga atgaagactg taaaagaaaa gaaggatgc cagagattga 660
aaaaatctgc caagacttagg agggtaaccc agaggaaacc gtcttcagg cctgtttgt 720
ggctatgcct tcgagaaacct ggggatcccc aaaaatttagg ggaatttctt cagaaagaca 780
atatcagcgt gcattatttc tgcattatct tattctatcc gtcgcctcag agggggccagt 840
ccaacagagg tttccatgga ttctgcctg aagacatcaa aaaggaggcg gccccggctt 900
cttaggaagat ctgtttgtg tgcagaaaa agggagctgc tatcaactgc cagaaggatc 960
agtgcctcag aaacttccat ctgccttgcg cccaaagaaag gggttgcctt tcacaatttt 1020
ttggagagta caaatcattt tgcacaaaaatcgcctt acagaacatc caacatgggc 1080
atgtggggga gggaaagctgc atcttatgtt gtgaagactt atcccaacag agtgttggaa 1140
acatccagag cccgtttgtt agtcaaggca tctaccaccc caagtgcata cagaaatatg 1200
cccacacatc agcaaagcat ttcttcaaat gtccacagtg taacaatcga aaagagtttc 1260
ctcaagaaaaat gctgagaatg ggaattcata ttccagacag agatgctgcc tggaaactcg 1320
agccaggggc ttctcagac ttatatcagc gctatcagca ctgtgtgcc cccatctgtc 1380
cgtatgaaca aggagagac agctttgagg atgaagggag gtggtgcctc attctgtgt 1440
ctacatgcgg atcccacggc acccacaggg actgcctc tcttagattt aacagtaaga 1500
aatggagtg tgaggagtgt tcacactgcg cagccacaga ctacatactt gaaaactcag 1560
gggacatccc ttgtgcagc agcacctcc accctgagga acatttctgc agagacaaca 1620
ccttggaaaa gaatccgggc ctttcttggc ctgattggcc agaacctcc ttatttagaaa 1680
agccagagtc ctctcggtgc aggaggagct actcctggag gtccaaagggt gtcagaatca 1740
ctaacagctg caaaaaatcc aagtaacacc ttctgagtag ctgctgtccc acacaatagg 1800
gtatgaagct ggcgcctcc atcgggtttt gggagggagc actctgggac tgtgagacaa 1860
ggaagcaggg ccagcagtga gactatgagc caagcaaaga gaagtctcag tggagcatga 1920
ggagggagca gtccagatgc caacaaggaa atgcgtttat ggctacaaga gtgcctctc 1980
tttctctcc tctccctccca ccaaggattc ttccacctt atcttgcattt catatgcctc 2040
ttcttacttc acccatgttt gttgttatgc aaataaaaggat ttctctccc aaaaaaaaaaa 2100
aaaaaaaaaaaa aaaaaaaaaaa aaaaaaaaaaa aa 2132

<210> 14
<211> 381
<212> PRT
<213> *Homo sapiens*

<400> 14

Met Lys Thr Val Lys Glu Lys Glu Cys Gln Arg Leu Arg Lys Ser
 1 5 10 15
 Ala Lys Thr Arg Arg Val Thr Gln Arg Lys Pro Ser Ser Gly Pro Val
 20 25 30
 Cys Trp Leu Cys Leu Arg Glu Pro Gly Asp Pro Glu Lys Leu Gly Glu
 35 40 45
 Phe Leu Gln Lys Asp Asn Ile Ser Val His Tyr Phe Cys Leu Ile Leu
 50 55 60
 Ser Ser Lys Leu Pro Gln Arg Gly Gln Ser Asn Arg Gly Phe His Gly
 65 70 75 80
 Phe Leu Pro Glu Asp Ile Lys Lys Glu Ala Ala Arg Ala Ser Arg Lys
 85 90 95
 Ile Cys Phe Val Cys Lys Lys Gly Ala Ala Ile Asn Cys Gln Lys
 100 105 110
 Asp Gln Cys Leu Arg Asn Phe His Leu Pro Cys Gly Gln Glu Arg Gly
 115 120 125
 Cys Leu Ser Gln Phe Phe Gly Glu Tyr Lys Ser Phe Cys Asp Lys His
 130 135 140
 Arg Pro Thr Gln Asn Ile Gln His Gly His Val Gly Glu Glu Ser Cys
 145 150 155 160
 Ile Leu Cys Cys Glu Asp Leu Ser Gln Gln Ser Val Glu Asn Ile Gln
 165 170 175
 Ser Pro Cys Cys Ser Gln Ala Ile Tyr His Arg Lys Cys Ile Gln Lys
 180 185 190
 Tyr Ala His Thr Ser Ala Lys His Phe Phe Lys Cys Pro Gln Cys Asn
 195 200 205
 Asn Arg Lys Glu Phe Pro Gln Glu Met Leu Arg Met Gly Ile His Ile
 210 215 220
 Pro Asp Arg Asp Ala Ala Trp Glu Leu Glu Pro Gly Ala Phe Ser Asp
 225 230 235 240
 Leu Tyr Gln Arg Tyr Gln His Cys Asp Ala Pro Ile Cys Pro Tyr Glu
 245 250 255
 Gln Gly Arg Asp Ser Phe Glu Asp Glu Gly Arg Trp Cys Leu Ile Leu
 260 265 270
 Cys Ala Thr Cys Gly Ser His Gly Thr His Arg Asp Cys Ser Ser Leu
 275 280 285
 Arg Phe Asn Ser Lys Lys Trp Glu Cys Glu Glu Cys Ser Pro Ala Ala
 290 295 300
 Ala Thr Asp Tyr Ile Pro Glu Asn Ser Gly Asp Ile Pro Cys Cys Ser
 305 310 315 320

Ser	Thr	Phe	His	Pro	Glu	Glu	His	Phe	Cys	Arg	Asp	Asn	Thr	Leu	Glu
				325					330					335	

Glu	Asn	Pro	Gly	Leu	Ser	Trp	Thr	Asp	Trp	Pro	Glu	Pro	Ser	Leu	Leu
				340				345					350		

Glu	Lys	Pro	Glu	Ser	Ser	Arg	Gly	Arg	Arg	Ser	Tyr	Ser	Trp	Arg	Ser
				355			360			365					

Lys	Gly	Val	Arg	Ile	Thr	Asn	Ser	Cys	Lys	Lys	Ser	Lys			
				370			375			380					

<210> 15
<211> 984
<212> DNA
<213> Homo sapiens

<400> 15
gtcacgtgga acctttaat ctcagcatcc ggagctccag gaagggaaaa tttcaagtca 60
gatagaattc tatataacc atttcttgg aaccttcagc cctcaagatt ccaacatcat 120
gacctcaagt tcaacacagt tgccttagt cctcatgtca ctgcctttgg tgctgcctgt 180
tgtggaaagca gtagaagccg gtgatgcaat cgccctttg ttaggtgtgg ttctcagcat 240
tacaggcatt tgcctgtct tgggggtata tgacacaaaa agaaatggac agatgtgact 300
ttgaaaggcc tactgagtca aacctcaccct tgaaaacctt tgcgcctttag aggctaaacc 360
tgagatttgg tgcgtgaaag gttccaagaa tcagtaataa agggagttt acattttca 420
ttgtttccat gaaatggcaa caaacataca ttataaatt gaaaaaaaaa tgtttcttt 480
acaacaaaata atgcacagaa aaatgcagcc tataattgc tagttagta gtcaaagaag 540
taagatggct gaaatttaca taagtaatat ttcataatct tagaatttctc tcaaagcatg 600
tgaaatagga agaaggaagt tcttgcctc aatcttagga aatcaccact gttcggttat 660
aatcactgcc tcttgaatcg ttgaggagtc tttaaattt gatttttttt ttgttgtctc 720
ccaaatgttatttata gatatcagag agtcaggcaa aaaggaaaaac ttttatctct 780
agggaaaaaaaaa cattttagaaa aatgtattca gtgtatctaa tactgaaaatg cgaaaaaaa 840
tttaatgtta aaaaaaaaaact atagacattg acatggaaaa gagatTTTat gtttgaaaa 900
aaaaacttta tattaactga gtaacatcct cctgatgaga agtactatataa taaatataaa 960
cccattatgt tataaaaaaaaaa aaaa 984

<210> 16
<211> 59
<212> PRT
<213> Homo sapiens

<400> 16
Met Thr Ser Val Ser Thr Gln Leu Ser Leu Val Leu Met Ser Leu Leu
1 5 10 15
Leu Val Leu Pro Val Val Glu Ala Val Glu Ala Gly Asp Ala Ile Ala
20 25 30
Leu Leu Leu Gly Val Val Leu Ser Ile Thr Gly Ile Cys Ala Cys Leu
35 40 45
Gly Val Tyr Ala Arg Lys Arg Asn Gly Gln Met
50 55

<210> 17
<211> 28
<212> DNA
<213> Homo sapiens

<400> 17	
gttcctacag cggtagaggt gaaatgtg	28
<210> 18	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 18	
ccgatacacc aaagtctcat ccctaaat	28
<210> 19	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 19	
gagctagtgt gaaggacaat aagcagaa	28
<210> 20	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 20	
gtcgcttaaca tcagaactaa cagattca	28
<210> 21	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 21	
gagatactgc aaatgaattt acacgggt	28
<210> 22	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 22	
gtcacactta actcccatca cccgaaag	28
<210> 23	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 23	
tctgaggcac tgatcttct ggcagttg	28
<210> 24	
<211> 28	
<212> DNA	
<213> Homo sapiens	
<400> 24	
tgagggctga aggttccaaa gaaatggt	28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18724

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :435/69.1, 252.3, 320.1; 536/23.1, 23.5, 24.31; 530/350; 514/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 252.3, 320.1; 536/23.1, 23.5, 24.31; 530/350; 514/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Dialog, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database GENBANK on STN, EST Accession No. R91686, HILLIER et al. The WashU-Merck EST Project. 25 August 1995.	1-5, 11
Y	Database GENBANK on STN, EST Accession No. AA033930, HILLIER et al. The WashU-Merck EST Project. 09 May 1997.	1-5, 11
Y	Database GENBANK on STN, Accession No. R76679, HILLIER et al. The WashU-Merck EST Project. 06 June 1995.	1-5, 11

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 OCTOBER 1998

Date of mailing of the international search report

30 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer

ENRIQUE D. LONGTON For

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18724

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-11

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18724

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

The Abstract does not meet the requirements of PCT Rule 8.1. The new Abstract is:

Novel polynucleotides and proteins encoded by or related to SEQ ID NO:1 and SEQ ID NO:2 are disclosed.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18724

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12N 15/00, 1/21, 15/63, 15/11; C07H 21/04, 21/02; C07K 14/00; A61K 38/00**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-11, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:1 and SEQ ID NO:2.

Group II, claim(s) 12-14, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:3 and SEQ ID NO:4.

Group III, claim(s) 15-17, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:5 and SEQ ID NO:6.

Group IV, claim(s) 18-20, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:7 and SEQ ID NO:8.

Group V, claim(s) 21-23, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:9 and SEQ ID NO:10.

Group VI, claim(s) 24-26, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:11 and SEQ ID NO:12.

Group VII, claim(s) 27-29, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:13 and SEQ ID NO:14.

Group VIII, claim(s) 30-32, drawn to polynucleotide and polypeptide sequences encoded by or related to SEQ ID NO:15 and SEQ ID NO:16.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The DNA and protein sequences of each of the separate groups are not related to each other structurally or functionally except by virtue of the fact that they encode secreted proteins. Therefore, the inventions do no relate to a single inventive concept under PCT Rule 13.1.